Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty

Table 4

The distribution of the patients without HPG axis suppression according to subgroups () (%).

Treatment; duration	CPP ()	RP-PP ()	AP ()
3rd month	2 (9.5%)	2 (9.5%)	5 (25%)
6th month	1 (5%)	0	4 (20%)
9th month	0	0	3 (15%)
12th month	0	0	0

CPP: central precocious puberty, RP-PP: rapidly progressive precocious puberty, and AP: advanced puberty.